Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180336 | 1.00 | SLC6A4 (0.66) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17865626 | 0.90 | SLC6A4 (0.77) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18162763 | 0.87 | SLC6A4 (0.59) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19285610 | 0.81 | TAAR1 (0.62) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15901777 | 0.79 | SIGMAR1 (0.58) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10813549 | 0.79 | SIGMAR1 (0.68) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29059547 | 0.78 | SIGMAR1 (0.81) | SLC6A4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9594275 | 0.78 | GAA (0.44) | SLC6A4SIGMAR1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL28579561 | 0.77 | TAAR1 (0.67) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.76 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312183-B1 | DEUTERATED MORPHINE DERIVATIVES FOR USE IN ANALGESIA | UNIV SZEGEDI (HU) | 2020-06-17 | — | — | EP | disclosed |
| EP-3312183-A1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2018-04-25 | — | — | EP | disclosed |
| EP-2986612-B1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2017-06-07 | — | — | EP | disclosed |
| US-9447108-B2 | Deuterated morphine derivatives | Szegedi Tudományegyetem (HU) | 2016-09-20 | — | — | US | disclosed |
| US-20160052931-A1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2016-02-25 | — | — | US | disclosed |
| EP-2986612-A1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014170704-A1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052931-A1 | DEUTERATED MORPHINE DERIVATIVES | OPRD1, OPRM1, OPRK1 | SLC6A4 1493/4885SIGMAR1 5/4885CYP1A2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.